Yahoo Finance • last month
Data from BriaCell and the US National Cancer Institute (NCI) support the cancer cell killing potential of BriaCell’s Bria-OTS+ platformBria-OTS+, a novel personalized,off-the-shelf, semi-allogeneic cellular immunotherapy may address urgen... Full story
Yahoo Finance • 2 months ago
* BriaCell Therapeutics (NASDAQ:BCTX [https://seekingalpha.com/symbol/BCTX]) will consolidate its common shares on a 1-for-10 basis to meet Nasdaq listing requirements. * The reverse split is expected to become effective on August 25,... Full story
Yahoo Finance • 2 months ago
PHILADELPHIA and VANCOUVER, British Columbia, Aug. 21, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel... Full story
Yahoo Finance • 2 months ago
PHILADELPHIA and VANCOUVER, British Columbia, Aug. 13, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ), (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops nove... Full story
Yahoo Finance • 2 months ago
PHILADELPHIA/VANCOUVER - BriaCell Therapeutics Corp. (NASDAQ:BCTX, TSX: BCT), a clinical-stage biotechnology company with a market capitalization of $2.5 million and an overall "WEAK" InvestingPro Financial Health score of 1.36, announced... Full story
Yahoo Finance • 2 months ago
PHILADELPHIA and VANCOUVER, British Columbia, July 31, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel im... Full story
Yahoo Finance • 2 months ago
PHILADELPHIA/VANCOUVER - BriaCell Therapeutics Corp. (NASDAQ:BCTX, TSX:BCT), a micro-cap biotechnology company with a market value of $2.5 million, announced Wednesday it has been granted New Zealand Patent No. 785587 for its whole-cell ca... Full story
Yahoo Finance • 2 months ago
PHILADELPHIA and VANCOUVER, British Columbia, July 30, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel im... Full story
Yahoo Finance • 2 months ago
TILsRx platform designed to overcome immune suppression and T cell exhaustion to activate tumor-infiltrating lymphocytes (TILs) Multivalent technology enables simultaneous engagement of multiple cancer-associated and immune pathway targets... Full story
Yahoo Finance • 3 months ago
PHILADELPHIA and VANCOUVER, British Columbia, July 25, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel... Full story
Yahoo Finance • 3 months ago
Investing.com – U.S. stocks were mixed after the close on Tuesday, as gains in the Technology, Telecoms and Industrials sectors led shares higher while losses in the Basic Materials, Healthcare and Financials sectors led shares lower. At... Full story
Yahoo Finance • 3 months ago
Investing.com - H.C. Wainwright has reiterated a Buy rating and $32.00 price target on Briacell Therapeutics (NASDAQ:BCTX), representing significant upside from the current price of $2.07. The bullish stance follows promising survival data... Full story
Yahoo Finance • 4 months ago
(RTTNews) - Biotechnology company BriaCell Therapeutics Corp. (BCTX) announced Tuesday that the independent Data Safety Monitoring Board (DSMB) has completed its third scheduled safety data review of BriaCell's pivotal Phase 3 study of Bri... Full story
Yahoo Finance • 2 years ago
After only 3 cycles, patient experienced a remarkable improvement of eye-bulging “proptosis” caused by orbital metastatic breast cancer tumor behind the eye. Significant ocular pain reduction recorded.Heavily treated patient had 7 prior fa... Full story
Yahoo Finance • 2 years ago
PHILADELPHIA and VANCOUVER, British Columbia, June 27, 2023 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage immunotherapy company driven to fight cancer and... Full story
Yahoo Finance • 2 years ago
Prevail Partners, LLC to purchase 463,408 BriaCell common shares at a price of $8.63 for gross proceeds of $4 million, representing a 20% premium to the trailing thirty (30) trading day VWAP. Prevail InfoWorks, Inc. to act as Contract Rese... Full story
Yahoo Finance • 2 years ago
15 of 18 patients remain alive of those recruited since the study reopened in 2021. Longer than expected patient survival data highlights tolerability and clinical effectiveness of BriaCell’s combination treatment.The Bria-IMT™ combination... Full story